(Q44452193)

3 December 2017

title

Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome (English)

1 reference

3 December 2017

0 references

Strupp C

1

1 reference

3 December 2017

Hildebrandt B

2

1 reference

3 December 2017

Germing U

3

1 reference

3 December 2017

Haas R

4

1 reference

3 December 2017

Gattermann N

5

1 reference

3 December 2017

publication date

1 June 2003

1 reference

3 December 2017

1 reference

3 December 2017

volume

17

1 reference

3 December 2017

issue

6

1 reference

3 December 2017

page(s)

1200-1202

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402894

3 December 2017

exact match

0 references

cites work

Thalidomide for the treatment of patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402894

Proposals for the classification of the myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402894

Thalidomide in agnogenic and secondary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402894

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402894

The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402894

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402894

21 January 2018

Identifiers

DOI

10.1038/SJ.LEU.2402894

1 reference

3 December 2017

1 reference